SEC Comment Letter 0000000000-24-005309 to Petros Pharmaceuticals, Inc. (PTPI)
Petros Pharmaceuticals, Inc.
Date: May 9, 2024 · CIK: 0001815903 · Accession: 0000000000-24-005309
AI Filing Summary & Sentiment
File numbers found in text: 333-279116
Letter
United States securities and exchange commission logo May 9, 2024 Fady Boctor Chief Commercial Officer Petros Pharmaceuticals, Inc. 1185 Avenue of the Americas, 3rd Floor New York, NY 10036 Re:Petros Pharmaceuticals, Inc. Registration Statement on Form S-3 Filed May 3, 2024 File No. 333-279116 Dear Fady Boctor: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Doris Stacey Gama at 202-551-3188 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Rick Werner, Esq.
Show Raw Text
United States securities and exchange commission logo
May 9, 2024
Fady Boctor
Chief Commercial Officer
Petros Pharmaceuticals, Inc.
1185 Avenue of the Americas, 3rd Floor
New York, NY 10036
Re:Petros Pharmaceuticals, Inc.
Registration Statement on Form S-3
Filed May 3, 2024
File No. 333-279116
Dear Fady Boctor:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Doris Stacey Gama at 202-551-3188 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Rick Werner, Esq.